CTLA4 and neoplasm: Upon reaching the tumor, the outer domain is cleaved by membrane type-serine protease 1 (MT-SP1) present in the tumor microenvironment, leading to enhanced localization of anti-CTLA4 without causing significant treatment-associated toxicity.